---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-005980"
form_type: "8-K"
ticker: "SNOA"
cik: "0001367083"
company_name: "Sonoma Pharmaceuticals, Inc."
filed_at: "2024-08-23T23:59:59+00:00"
generated_at: "2026-05-31T07:48:53.741191+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Sonoma Pharmaceuticals files prospectus supplement for existing at-the-market equity offering

## Summary
- Company entered into Equity Distribution Agreement with Maxim Group LLC on Dec 15, 2023, amended March 8, 2024.
- Prospectus supplement filed Aug 23, 2024 for sales of common stock under effective S-3 registration statement.
- Shares may be offered and sold through Maxim as sales agent or principal, at-the-market.
- Legal opinion of Polsinelli PC regarding share validity filed as Exhibit 5.1.

## SEC filing metadata
- accession: 0001683168-24-005980
- form_type: 8-K
- ticker: SNOA
- cik: 0001367083
- company_name: Sonoma Pharmaceuticals, Inc.
- filed_at: 2024-08-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367083/000168316824005980/0001683168-24-005980-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367083/000168316824005980/sonoma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-005980
- JSON: https://secwatch.observer/filing/0001683168-24-005980.json
- Plain text: https://secwatch.observer/filing/0001683168-24-005980.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.